Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15382
|
| Title: | Low-dose computed tomography screening in relatives with a family history of lung cancer |
| Authors: | Wang, CL;Hsu, KH;Chang, YH;Ho, CC;Chiang, CJ;Chen, KC;Cheung, YC;Huang, PC;Chen, YR;Chen, CY;Hsu, CP;Hsia, JY;Chen, HY;Yang, SY;Li, YJ;Yang, TY;Tseng, JS;Chuang, CY;Hsiung, CA;Chen, YM;Huang, MS;Yu, CJ;Chen, KY;Su, WC;Chen, J;Yu, SL;Chen, CJ;Yang, PC;Tsai, YH;Chang, GC |
| Contributors: | Institute of Population Health Sciences;Institute of Molecular and Genomic Medicine |
| Abstract: | Introduction:The role of a family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated with long-term follow-up. Methods:A multicenter prospective study with up to three rounds of annual LDCT screening was conducted to determine the detection rate of lung cancer (LC) in asymptomatic first- or second-degree relatives of LCFH. Results:From 2007 to 2011, there were 1102 participants enrolled, including 805 and 297 from simplex and multiplex families (MFs), respectively (54.2% women and 70.0% never-smokers). The last follow-up date was May 5, 2021. The overall LC detection rate was 4.5% (50 of 1102). The detection rate in MF was 9.4% (19 of 202) and 4.4% (4 of 91) in never-smokers and in those who smoked, respectively. The corresponding rates for simplex families were 3.7% (21 of 569) and 2.7% (6 of 223), respectively. Of these, 68.0% and 22.0% of cases with stage I and IV diseases, respectively. LC diagnoses within a 3-year interval from the initial screening tend to be younger, have a higher detection rate, and have stage I disease; thereafter, more stage III–IV disease and 66.7% (16 of 24) with negative or semipositive nodules in initial computed tomography scans. Within the 6-year interval, only maternal (modified rate ratio = 4.46, 95% confidence interval: 2.32–8.56) or maternal relative history of LC (modified rate ratio = 5.41, 95% confidence interval: 2.84–10.30) increased the risk of LC. Conclusions:LCFH is a risk factor for LC and is increased with MF history, among never-smokers, younger adults, and those with maternal relatives with LC. Randomized controlled trials are needed to confirm the mortality benefit of LDCT screening in those with LCFH. |
| Date: | 2023-11-01 |
| Relation: | Journal of Thoracic Oncology. 2023 Nov 1;18(11):1492-1503. |
| Link to: | https://doi.org/10.1016/j.jtho.2023.06.018 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1556-0864&DestApp=IC2JCR |
| Appears in Collections: | [熊昭] 期刊論文
[張雅媗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| NMG2023110601.pdf | | 419Kb | Adobe PDF | 149 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
